Agenda. Q progress (15 mins) Emma Walmsley, Chief Executive Officer. Q financial results (15 mins)
|
|
- Egbert Lambert
- 5 years ago
- Views:
Transcription
1 Emma Walmsley, CEO
2 Agenda Q progress (15 mins) Q financial results (15 mins) Emma Walmsley, Chief Executive Officer Simon Dingemans, Chief Financial Officer Q&A (30 mins) Break (15 mins) R&D update (60 mins) Dr Hal Barron Chief Scientific Officer and President R&D Q&A (60 mins) Informal reception 2
3 Q&A panel David Redfern Chief Strategy Officer, Chairman of ViiV Luke Miels President, Global Pharmaceuticals Brian McNamara CEO, GSK Consumer Healthcare Luc Debruyne President Global Vaccines Axel Hoos Oncology Therapy Area Kim Smith Global Research and Medical Strategy, ViiV Gijs van den Brink Immunoinflammation R&D Emmanuel Hanon R&D Vaccines John Lepore Patrick VallanceR&D Pipeline President R&D Kevin Sin R&D Pharmaceuticals Business Development Kate Knobil Chief Medical Officer Tony Wood Platform Tech & Science Pauline Williams Global Health 3
4 3 long-term priorities for all 3 businesses Innovation Performance Trust Culture 4
5 CER Sales growth in all 3 businesses; improved Group operating margin Pharmaceuticals +1% Vaccines +16% Consumer Healthcare +3% New Respiratory products +37%* HIV sales +11%; dolutegravir +18% Shingrix reported sales of 167 million US vaccines sales +61% Meningitis sales -3% Wellness sales +1%; Oral health sales +5%; Nutrition sales +1%; Skin sales +8% Group sales growth of +4% 80bp improvement in Group Adjusted operating margin Adjusted EPS growth of +10% FCF of 492 million 2018 guidance upgraded All growth rates and margin changes at CER. The definitions and reconciliations for non-ifrs measures are set out on page 39 of our Q earnings release *New Respiratory includes the Ellipta portfolio and Nucala 5
6 Respiratory: successfully transitioning to new portfolio Strong Trelegy launch reflects commercial prioritisation Nucala building momentum in a growing market New Respiratory products continue to perform Increased investment in the market Strong uptake in Europe Q2 Sales m +37%* COLUMBA long term safety data presented at ATS; gaining traction with physicians Other indications offer upside potential: COPD, HES, NP Q Q COPD: chronic obstructive pulmonary disease; HES: hypereosinophilic syndrome; NP: nasal polyposis * All growth rates and margin changes at CER. New Respiratory includes the Ellipta portfolio and Nucala 6
7 TRx shares Portfolio performance on track with GEMINI studies building confidence in 2DR outlook Dolutegravir maintaining leadership position in STR/Core Agent market Non inferior virologic outcomes and no emergent resistance seen 30% 25% Weekly TRx Shares by Product (STR+Core agent) 28.0% GEMINI studies demonstrate non-inferior virologic outcomes for DTG + 3TC vs DTG + TDF/FTC at Week 48 20% 15% 10% 5% 0% 13.8% (Tivicay) 13.4% (Triumeq) 4.9% 0.8% Rates of virologic success were high regardless of baseline viral load No participant who experienced virologic failure developed treatment emergent resistance to NRTI or INSTI in either arm Drug related adverse events were low in both arms but favoured DTG+3TC Tivicay Triumeq DTG Total Juluca Competitor Regulatory submissions planned before end 2018 Source: IQVIA NPA w/e 13 Jul
8 Shingrix: continued strong demand Demand significantly higher than 2017 Building a new standard of prevention 160, , , ,000 80,000 60,000 40,000 20,000 - Weekly Shingrix TRx volume vs 2017 competitor (weekly pharmacy administered doses) Weekly Shingrix TRx's - Actual Weekly competitor TRx PY Recommendations driving market demand 99% of known US market share 1 Strong recommendation received in Canada during Q2 2 Q sales of 167 million Capacity strong and increasing More than 3m doses administered 3 in US since launch Supplies increased and accelerated to meet demand, with doses shipping on regular basis Capacity to vaccinate more patients in 2018 than the total vaccinated in 2017 Sales expectations for 2018 increased to m Source: IQVIA NPA weekly TRx data 1. IQVIA data, represents ~60% of the market 2. National Advisory Committee on Immunization (Canada): A Strong recommendation applies to most populations/individuals and should be followed unless a clear and compelling rationale for an alternative approach is present 3. Doses administered includes retail data from IQVIA reporting plus an estimate of non-retail use (~60 / 40 split) as of 29 June
9 Driving our growth outlook beyond 2020 Continuing growth drivers Tivicay and Triumeq Nucala and Ellipta portfolio Bexsero and Menveo Shingrix Trelegy Juluca tafenoquine Nucala (COPD) DTG+3TC CAB+RPV Trelegy (asthma) 916 (BCMA) fostemsavir (TLR4) 165 (agm-csf) 254 (HIV MI) 404/ 836 (HBV) 557 (PI3Kd) 595 (PRMT5 inhibitor) 609 (ICOS) 656 (leucyl trna) 672 (IBAT) 745 (TRPV4) 756 (CXCR2) 762 (BET inhibitor) 794 (NY ESO-1) 847 (IL33R) 863 (HIF-PHI) 944 (topoisomerase IV inhibitor) 998 (OX40) CAB PrEP (HIV) Benlysta+ rituximab (SLE) Base business portfolio optimisation; limited exposure to patent expiries Consumer Health power brands 9
10 Capital allocation framework Key priorities for capital Innovation Invest in the business 1. Pharma pipeline including BD 2. Consumer Put (buy out completed June 2018) 3. Vaccines capacity Performance Improved cash generation Shareholder returns 80p per share expected for 2018 Focus on rebuilding free cash flow cover over time Target 1.25x to 1.5x FCF cover before returning to dividend growth Trust M&A Strict discipline on returns 10
11 Funding future growth Delivering growth Investing in our business Improved operating leverage Stronger cash generation Financial efficiencies 11
Q Results. 25 April 2018
Q1 2018 Results 25 April 2018 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group s current expectations
More informationAccelerating our IPT strategy
Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based
More informationPress release Third quarter 2018
Third quarter 2018 Issued: Wednesday, 31 October 2018, London U.K. GSK delivers Q3 sales of 8.1 billion, +3% AER, +6% CER Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER Financial
More informationQ results. 27 July 2016
Q2 2016 results 27 July 2016 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group s current expectations
More informationSir Andrew Witty CEO full year results 8 February 2017
Sir Andrew Witty CEO 2016 full year results 8 February 2017 Significant progress made in 2016 Core EPS +12% (CER), at top end of upgraded guidance for 2016 3 growth businesses New product contribution
More informationQ2 and financial outlook. Simon Dingemans, CFO
Q2 and financial outlook Simon Dingemans, CFO Headline results Continued sales growth and investment in the future Q2 2017 Reported growth % H1 2017 Reported growth % m AER CER m AER CER Turnover 7,320
More informationPress release Full year and fourth quarter 2018
Full year and fourth quarter 2018 Issued: Wednesday, 6 February 2019, London U.K. GSK delivers sales, earnings and cash flow growth in 2018 Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p
More informationPress release First quarter 2018
First quarter 2018 Issued: Wednesday, 25 April 2018, London U.K. GSK delivers Q1 sales of 7.2 billion, -2% AER, +4% CER Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER Significant
More informationPress release Full year and fourth quarter 2017
Full year and fourth quarter 2017 Issued: Wednesday, 7 February 2018, London U.K. GSK delivers improvements in sales, margins and cash flow in 2017 Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p,
More informationPress release Second quarter 2016
Second quarter 2016 Issued: Wednesday, 27 July 2016, London U.K. Results Announcement for the second quarter 2016 and Half-yearly Financial Report for the half-year 2016 GSK delivers further progress against
More informationAnnual Summary I am proud to work on our respiratory portfolio and know how important these medicines are to the lives of patients.
Annual Summary I am proud to work on our respiratory portfolio and know how important these medicines are to the lives of patients. Julie, GSK respiratory packaging operator, Ware, UK Chairman s statement
More informationTURNOVER 7,310 9,870. Cost of sales (2,310) (3,116) Gross profit 5,000 6,754
Income statement Three months ended 30 June 2018 TURNOVER 7,310 9,870 Cost of sales (2,310) (3,116) Gross profit 5,000 6,754 Selling, general and administration (2,457) (3,320) Research and development
More informationTURNOVER 8,092 10,633. Cost of sales (2,636) (3,465) Gross profit 5,456 7,168
Income statement Three months ended 30 September 2018 TURNOVER 8,092 10,633 Cost of sales (2,636) (3,465) Gross profit 5,456 7,168 Selling, general and administration (2,527) (3,316) Research and development
More informationTURNOVER 30,186 39,242. Cost of sales (10,342) (13,445) Gross profit 19,844 25,797
Income statement Year ended 31 December 2017 TURNOVER 30,186 39,242 Cost of sales (10,342) (13,445) Gross profit 19,844 25,797 Selling, general and administration (9,672) (12,574) Research and development
More informationPre-Quarterly Results Communication Q4 2018
Issued: Friday, 11 th January 2019 Pre-Quarterly Results Communication Contents New information for... 2 Foreign exchange... 2 Basic weighted average number of shares (WANS)... 4 Dividend... 4 Factors
More informationRemuneration report Chairman s annual statement
113 Strategic report Governance and remuneration Financial statements Investor information Remuneration In this section Chairman s annual statement 114 Annual report on remuneration 116 Remuneration policy
More informationPre-Quarterly Results Communication Q1 2018
Issued: Tuesday, 10 th April 2018 Pre-Quarterly Results Communication 2018 Contents New information for 2018... 2 Foreign exchange... 2 Currency impact 2018... 4 Basic weighted average number of shares
More informationHello and welcome to this discussion of GSK s first quarter results for 2015.
GSK Simon Dingemans Hello and welcome to this discussion of GSK s first quarter results for 2015. We have issued a press release today setting out in detail our views of the prospects for the Group now
More informationGSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share
Issued: Wednesday, 22 October 2014, London U.K. Results Announcement for the third quarter 2014 GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share Core
More informationGLAXOSMITHKLINE 32 ND ANNUAL JP MORGAN HEALTHCARE CONFERENCE Simon Dingemans CFO. Tuesday, 14 January 2014
GLAXOSMITHKLINE 32 ND ANNUAL JP MORGAN HEALTHCARE CONFERENCE Simon Dingemans CFO Tuesday, 14 January 2014 It is a pleasure to be here this morning and to be able to update you on where GSK is as we start
More informationGSK delivers 2014 core EPS of 95.4p (-1% CER excluding divestments) and dividend of 80 pence per share (+3%)
Issued: Wednesday, 4 February 2015, London U.K. Unaudited Preliminary Results Announcement for the year ended 31 December 2014 GSK delivers 2014 core EPS of 95.4p (-1% CER excluding divestments) and dividend
More informationTURNOVER 5,888 9,065. Cost of sales (2,005) (3,089)
Income statement Three months ended 30 June 2015 TURNOVER 5,888 9,065 Cost of sales (2,005) (3,089) Gross profit 3,883 5,976 Selling, general and administration (2,541) (3,910) Research and development
More informationH1 Results July 2012
H1 Results 2012 25 July 2012 Andrew Witty Chief Executive Officer Simon Dingemans Chief Financial Officer Continued execution of our strategy in a difficult external environment Grow a diversified global
More informationFull Year Results, February 2014
Full Year Results, 2013 5 February 2014 Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company
More informationGSK delivers 2014 core EPS of 95.4p (-1% CER excluding divestments) and dividend of 80 pence per share (+3%)
Final Results Released : 04/02/2015 RNS Number : 0399E GlaxoSmithKline PLC 04 February 2015 Issued: Wednesday, 4 February 2015, London U.K. Unaudited Preliminary Results Announcement for the year ended
More informationJazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination. Bruce Cozadd, Chairman and CEO
Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination Bruce Cozadd, Chairman and CEO Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform
More informationFull Year Results th February 2012
Full Year Results 2011 7 th February 2012 Sir Andrew Witty Chief Executive Officer Simon Dingemans Chief Financial Officer Delivering our strategy Grow a diversified global business Deliver more products
More informationGlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, September 2017
GlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, 2017 1 September 2017 GlaxoSmithKline Pharmaceuticals Limited Analyst Update 1 September 2017 A. Vaidheesh, Managing Director Andrew Aristidou,
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationUDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017
UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking
More informationImportant Notice. Driving Profitable Growth FY2017 Q2. November 1, Christophe Weber President & Chief Executive Officer
Driving Profitable Growth FY2017 Q2 November 1, 2017 Christophe Weber President & Chief Executive Officer Important Notice Forward Looking Statements This presentation contains forward looking statements
More informationASX Announcement MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE
23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE Revenue of $243.3m, a decrease of 17% on 1HFY17 Adjusted EBITDA of $70.2m, down 36% on 1HFY17 Reported EBITDA of $23.0m, down 82% on 1HFY17
More informationFOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018
FOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018 0 Agenda and Speakers Joe Woody Chief Executive Officer Halyard Outlook and Update on Divestiture 2018 Priorities Steve Voskuil Chief Financial Officer
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Pulmatrix (Nasdaq/PULM) BUY
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationFinance Financial objectives, capital allocation, & long-term value creation. Marc Dunoyer, Executive Director, Chief Financial Officer
Finance Financial objectives, capital allocation, & long-term value creation Marc Dunoyer, Executive Director, Chief Financial Officer $53bn returned to shareholders over 10 years... 2004 2013 cash distributions
More informationTeva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019
Teva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationQ2 Results 2010 Presentation to Investors & Analysts. 21 st July 2010
1 Q2 Results 2010 Presentation to Investors & Analysts 21 st July 2010 Julian Heslop Chief Financial Officer 2 Financial summary Turnover Operating profit* EPS Free cash flow Q2 10 H1 10 m m 7,025 14,382
More informationFull Year 2016 Results
Full Year 2016 Results 1 Forward looking statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and
More informationQ1 Results David Brennan, CEO
Q1 Results 2012 David Brennan, CEO Q1 2012 First quarter results reflect challenging revenue picture Pipeline strengthened by: Amgen collaboration on 5 clinical stage projects in inflammation Agreement
More information1. The Board of Directors' report on the Company's activities in the past year.
AGENDA 1. The Board of Directors' report on the Company's activities in the past year. 2. Presentation of the Annual Report for adoption. 3. A proposal from the Board of Directors regarding the application
More informationQ Presentation to Investors & Analysts. 26 th July 2011
Q2 2011 Presentation to Investors & Analysts 26 th July 2011 Andrew Witty Chief Executive Officer Sustained underlying growth with contribution from Pharma, Consumer and Vaccines FY 2010 4.5% 1Q 2011 4%
More informationTeva Pharmaceutical Industries Ltd. Q November 1, 2018
Teva Pharmaceutical Industries Ltd. Q3 2018 November 1, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationGSK delivers 2012 core EPS of 112.7p and returns 6.3 billion to shareholders
Issued: Wednesday, 6 February 2013, London, U.K. Unaudited Preliminary Results Announcement for the year ended 31 December 2012 GSK delivers 2012 core EPS of 112.7p and returns 6.3 billion to shareholders
More informationREQUEST FOR PROPOSAL (RfP)
REQUEST FOR PROPOSAL (RfP) Title: Request for proposal for grants to support development, regulatory filing, and commercialization of Dolutegravir 10 mg scored dispersible tablets RfP Number: 0011-DTGPeds
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationUnique & Compelling Value Proposition. January 26, 2017
Unique & Compelling Value Proposition January 26, 2017 1 Today s Speakers Alex Gorsky Jean-Pierre Garnier Joaquin Duato Paul Stoffels Jean-Paul Clozel Dominic Caruso 2 Cautionary Note on Forward-Looking
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference John J. Greisch, President and CEO January 9, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform
More informationFinancial Year 1H19 Results
Financial Year 1H19 Results Investor presentation 20 November 2018 1 Agenda 1. 1H19 Summary 2. 1H19 Financial results 3. FY19 Outlook 4. Q&A 5. Appendix 2 1H19 Summary Skander Malcolm Chief Executive Officer
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationTHOMSON REUTERS. REUTERS/Stoyan Nenov THIRD-QUARTER 2015 RESULTS
THOMSON REUTERS REUTERS/Stoyan Nenov THIRD-QUARTER 2015 RESULTS Agenda Welcome / Introduction Frank Golden Third-Quarter 2015 & Highlights Jim Smith Financial Review Q3 2015 Stephane Bello Q & A Special
More informationRoche: Innovation & profitable growth Lazard Conference 15 November 2011
Roche: Innovation & profitable growth Lazard Conference 15 November 2011 Thomas Kudsk Larsen, Head of Investor Relations North America Eka Kortkhonjia, Investor Relations Officer This presentation contains
More informationImperial Brands (formerly known as Imperial Tobacco) AstraZeneca RESULTS SEASON. Stephen Lamacraft, 7 March 2016
The views expressed in this article are those of the author at the date of publication and not necessarily those of Woodford Investment Management Ltd. We re heading towards the end of one of the busiest
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Robert Abernathy Chairman and CEO
J.P. MORGAN HEALTHCARE CONFERENCE Robert Abernathy Chairman and CEO OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and conference call, including our 2016 outlook, expectations
More informationStrategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Important notice Forward-Looking Statements Medical Information
Strategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Christophe Weber, President & CEO Rudolf van Houten, Acting CFO & Group Financial Controller July 30, 2015 Important notice Forward-Looking
More informationQ4 and Full Year Results 2012
Q4 and Full Year Results 2012 Geoffrey McDonough (CEO) Alan Raffensperger (COO) Annika Muskantor (Interim CFO) Stockholm, 21 February 2013 Forward Looking Statements In order to utilize the Safe Harbor
More informationHealthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang
Healthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang Agenda Sector Overview SIM Portfolio Overview Additional Companies Assessed Stocks Recommendation Healthcare Sector:
More informationDelivering Outstanding Pharmacy Services
Delivering Outstanding Pharmacy Services 2015 ANNUAL REPORT PHARMERICA 2015 ANNUAL REPORT 1 PharMerica Overview PharMerica serves a broad spectrum of the pharmacy services market. PharMerica Corporation
More informationQ4 AND FULL YEAR 2017 UPDATE. March 1, 2018
Q4 AND FULL YEAR 2017 UPDATE March 1, 2018 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationStryker. Kevin A. Lobo Chairman and Chief Executive Officer
Stryker Kevin A. Lobo Chairman and Chief Executive Officer Disclaimer Forward-looking statement This presentation contains information that includes or is based on forward looking statements within the
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationViews on the Generics Market
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul, Turkey 15 th June 2007 Safe Harbor Except for
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationFinancial Results for Fiscal Year 2017 (Consolidated) May 9, 2018 Name of Listed Company: SHIONOGI & CO., LTD.
r Fiscal Year 2017 (Consolidated) May 9, 2018 Name of Listed Company: TD. Listed Exchanges: Section I of Tokyo Code: 4507 URL: http://www.shionogi.co.jp Representative: Isao Teshirogi, President and CEO
More information36th Annual J.P. Morgan Healthcare Conference
36th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January 11, 2018 Safe Harbor Statement Certain statements made during the course
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More information** The operating loss for H is after exceptional costs of 41k relating to the termination of the Biomoti acquisition
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six-month period
More informationQuarter ended 30 June Financial results & business update
Quarter ended 30 June 2013 Financial results & business update 29 July 2013 Disclaimer Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationTELECONFERENCE Q May 2015
TELECONFERENCE Q1 2015 6 May 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSECOND QUARTER 2017 EARNINGS CALL AUGUST 2, 2017
SECOND QUARTER 2017 EARNINGS CALL AUGUST 2, 2017 SECOND QUARTER EARNINGS CALL AGENDA CEO Transition Robert Abernathy Chairman Strategic Vision Joe Woody Chief Executive Officer Second Quarter Results and
More informationVectura Group plc Acquisition of Activaero
Vectura Group plc Acquisition of Activaero Chippenham, UK 13 March 2014: Vectura Group plc (LSE: VEC; Vectura or the Company ) announces the acquisition of Activaero GmbH ( Activaero ) for a total consideration
More informationCan you feel the buzz?
L I V E W E L L N E S S, C R E AT E L I F E S T Y L E. Can you feel the buzz? The Global Market for Hemp has surged as interest in High Quality Hemp products continues to grow. U.S. Consumer sales of hemp
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More informationStanding strong for payers and patients
Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE
More informationLINCARE HOLDINGS INC.
LINCARE HOLDINGS INC. Forward-Looking Statements Certain statements contained in this presentation constitute forward-looking statements. Such forwardlooking statements are based on management s current
More information2Q 19 Earnings Call Presentation. February 5, 2019
2Q 19 Earnings Call Presentation February 5, 2019 Agenda John Chiminski, Chair & Chief Executive Officer 2Q 19 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Business Update by Segment
More informationFOURTH QUARTER 2015 EARNINGS CALL. February 29, 2016
FOURTH QUARTER 2015 EARNINGS CALL February 29, 2016 FOURTH QUARTER EARNINGS CALL AGENDA Fourth Quarter Update Robert Abernathy, Chairman and Chief Executive Officer Fourth Quarter Results and 2016 Outlook
More informationQ EARNINGS CALL May 1, :00 am ET
Q1 2018 EARNINGS CALL May 1, 2018 9:00 am ET Forward-Looking Statements This presentation contains or may contain forward-looking statements within the meaning of Section 27a of the Securities Act of 1933,
More informationDriving Total Shareholder Return
ANALYST MEETING Driving Total Shareholder Return David Shedlarz Vice Chairman Agenda Total Shareholder Return (TSR) framework Key TSR drivers Business development Cost reduction Continuous improvement
More informationStanding strong for payers and patients
Standing strong for payers and patients Dr. Steve Miller, SVP, Chief Medical Officer Ben Bier, VP Investor Relations W I L L I A M B L A I R 3 7 TH ANNUAL G ROWTH STOCK C ONFERENCE 6.14.17 1 Safe harbor
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationRaymond James 38 th Annual Institutional Investor Conference. March 6, 2017
Raymond James 38 th Annual Institutional Investor Conference March 6, 2017 1 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation
More informationAccelerating Healthcare
Accelerating Healthcare Ingo Bank, CFO Philips Healthcare Name Jefferies Global Healthcare Conference, New York June 4 th, 203 Important information Forward-looking statements This document and the related
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationHill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016
Hill-Rom Fourth Quarter 2016 Financial Results November 3, 2016 Forward Looking Statements Certain statements in this presentation contain forward-looking statements, within the meaning of the Private
More informationHalf Yearly Report Interim Results for the six months ended 30 September 2014
21 November 2014 Collagen Solutions Plc (the "Company" or the Group ) Half Yearly Report Interim Results for the six months ended 30 September 2014 Collagen Solutions plc (AIM: COS), the developer and
More informationRisk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study
Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study Presented by Bill O Brien, FSA, MAAA Consulting Actuary Milliman Houston, TX (832) 878-4078 Preconference I Agenda
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationWE BELIEVE. We have a POWERFUL OPPORTUNITY to make healthcare BETTER TOGETHER. April 24, 2017
WE BELIEVE We have a POWERFUL OPPORTUNITY to make healthcare BETTER TOGETHER. April 24, 2017 1 IMPORTANT INFORMATION FOR INVESTORS In connection with the proposed transaction, Becton Dickinson and Company
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationEndo International plc
Endo International plc Q2 2015 Earnings Report August 10, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationConsolidated Financial Results for the 1st Quarter of Fiscal Year 2014
Consolidated Financial Results for the 1st Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer August 1, 2014 Notes on Disclosure Shift to IFRS and Core earnings From Q1 2014 Takeda
More informationLEM - Maintaining the Growth Momentum Half year results FY 2006/07
LEM - Maintaining the Growth Momentum Half year results FY 2006/07 Agenda Paul Van Iseghem President and CEO Ageeth Walti CFO Paul Van Iseghem President and CEO Highlights Half Year 2006/07 Business review
More informationSummary of Financial Statements for the Three Month Period Ended June 30, 2017 (IFRS, Consolidated) July 28, 2017
Period Ended (IFRS, Consolidated) July 28, 2017 Takeda Pharmaceutical Company Limited Stock exchange listings: Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative:
More informationLUMINEX CORPORATION. February 5 th, th Quarter and Full Year 2008 Results of Operations
LUMINEX CORPORATION 4 th Quarter and Full Year Results of Operations February 5 th, 2009 Patrick J. Balthrop, President and Chief Executive Officer Harriss T. Currie, Vice President and Chief Financial
More information